Press releases
- Press releases
- Browse
Press releases
RiboTargets, the structure-based drug discovery company that develops novel cancer and anti-bacterial therapeutics, announced today that it has extended its exclusive license with ASINEX for a further three years. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Dec 2010 - 19 pages - $99
Nov 2010 - 26 pages - $125
Nov 2009 - $15,200
Mar 2011 - 33 pages - $125
Jun 2011 - 34 pages - $125
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Nov 2010 - 40 pages - $500
Your selection
Browse By
- Therapeutic target
- Anti-oxidant
- Bladder cancer
- Bone cancer
- Brain cancer
- Breast cancer
- Cancer (other)
- Cancer side effects
- Cervical cancer
- Colorectal cancer
- Head and neck cancer
- Kaposi's sarcoma
- Kidney cancer
- Leukemia
- Liver cancer
- Lung cancer
- Lymphoma
- Ovarian cancer
- Pancreatic cancer
- Polyps
- Prostate cancer
- Skin cancer
- Stomach/Esophageal
- Testicular cancer
- Transplant
- Treatments
- Tumor (other)
- Vaginal Cancer
- Womb cancer
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us